The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...
Hosted on MSN2mon
Experts: 'Chikungunya Triggers Lifelong Arthritis In 13 % Of Total Patients;' 'Acupuncture Shows Promising Results In Neurological Disorder Treatement'Indore (Madhya Pradesh): “Chikungunya is causing lifelong arthritis in genetically prone individuals, affecting 13 per cent of the total patients falling prey to the vector-borne disease ...
The development of polyvalent immunoglobulins purified from human plasma samples of convalescent Chikungunya patients could benefit infected viremic mothers and newborns.
The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
Health officials have identified a group of patients showing symptoms of Chikungunya, including children and elderly ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...
At least five suspected cases of chikungunya were recorded in Davao City in January 2025. The residents who were suspected of ...
10d
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback